Original Communication| Volume 155, ISSUE 4, P640-649, April 2014

Blockage of CXCR2 suppresses tumor growth of intrahepatic cholangiocellular carcinoma

Published:January 06, 2014DOI:


      Complete operative resection is the only approach to cure for intrahepatic cholangiocellular carcinoma (ICC), but the disease’s prognosis is notably poor. A novel therapeutic approach is urgently required. CXC chemokine receptor 2 (CXCR2) has been associated with tumorigenesis and metastasis in human cancers. In this study, we investigated the suppressive effect of ICC growth by blocking CXCR2.

      Material and methods

      The role of CXCR2 was estimated using the human ICC cell lines, RBE and SSP25. CXCR2 small interfering RNA (siRNA) and an antagonist (SB225002) were used to block CXCR2. Proliferation assays, migration assays, and invasion assays were performed to confirm the suppressive effect of blocking CXCR2. Subcutaneous SSP25 tumors were established in athymic nude mice, and the mice were given SB225002. The expression of CXCR2 in ICC was determined by immunohistochemical staining of 34 ICC specimens. We investigated the relationship between CXCR2 expression and prognosis in ICC.


      The prognosis of patients who had higher CXCR2 expression in ICC was significantly poor (P = .004). CXCR2 siRNA treatment significantly suppressed CXCR2 expression in both RBE and SSP25. Cell proliferation, migration, and invasion were significantly suppressed by both CXCR2 siRNA and SB225002 compared with the control group. SB225002 also suppressed the growth of transplanted subcutaneous tumors (P = .02)


      Our results demonstrated that blocking CXCR2 clearly suppressed the development of ICC. Blocking CXCR2 may be a promising therapeutic approach for ICC.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Shaib Y.
        • El-Serag H.B.
        The epidemiology of cholangiocarcinoma.
        Semin Liver Dis. 2004; 24: 115-125
        • Park J.
        • Tadlock L.
        • Gores G.J.
        • et al.
        Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line.
        Hepatology. 1999; 30: 1128-1133
        • Isomoto H.
        • Mott J.L.
        • Kobayashi S.
        • et al.
        Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing.
        Gastroenterology. 2007; 132: 384-396
        • Kobayashi S.
        • Werneburg N.W.
        • Bronk S.F.
        • et al.
        Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells.
        Gastroenterology. 2005; 128: 2054-2065
        • Han C.
        • Leng J.
        • Demetris A.J.
        • et al.
        Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest.
        Cancer Res. 2004; 64: 1369-1376
        • Kiguchi K.
        • Carbajal S.
        • Chan K.
        • et al.
        Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma.
        Cancer Res. 2001; 61: 6971-6976
        • Ebnet K.
        • Vestweber D.
        Molecular mechanisms that control leukocyte extravasation: the selectins and the chemokines.
        Histochem Cell Biol. 1999; 112: 1-23
        • Homey B.
        • Muller A.
        • Zlotnik A.
        Chemokines: agents for the immunotherapy of cancer?.
        Nat Rev Immunol. 2002; 2: 175-184
        • Murphy C.
        • McGurk M.
        • Pettigrew J.
        • et al.
        Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer.
        Clin Cancer Res. 2005; 11: 4117-4127
        • Balkwill F.
        Cancer and the chemokine network.
        Nat Rev Cancer. 2004; 4: 540-550
        • Cheng W.L.
        • Wang C.S.
        • Huang Y.H.
        • et al.
        Overexpression of CXCL1 and its receptor CXCR2 promote tumor invasion in gastric cancer.
        Ann Oncol. 2011; 22: 2267-2276
        • Ijichi H.
        • Chytil A.
        • Gorska A.E.
        • et al.
        Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma.
        J Clin Invest. 2011; 121: 4106-4117
        • Jamieson T.
        • Clarke M.
        • Steele C.W.
        • et al.
        Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis.
        J Clin Invest. 2012; 122: 3127-3144
        • Lee Y.S.
        • Choi I.
        • Ning Y.
        • et al.
        Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis.
        Br J Cancer. 2012; 106: 1833-1841
        • Liu Z.
        • Yang L.
        • Xu J.
        • et al.
        Enhanced expression and clinical significance of chemokine receptor CXCR2 in hepatocellular carcinoma.
        J Surg Res. 2011; 166: 241-246
        • Nannuru K.C.
        • Sharma B.
        • Varney M.L.
        • et al.
        Role of chemokine receptor CXCR2 expression in mammary tumor growth, angiogenesis and metastasis.
        J Carcinog. 2011; 10: 40
        • Saintigny P.
        • Massarelli E.
        • Lin S.
        • et al.
        CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma.
        Cancer Res. 2013; 73: 571-582
        • Singh S.
        • Sadanandam A.
        • Varney M.L.
        • et al.
        Small interfering RNA-mediated CXCR1 or CXCR2 knock-down inhibits melanoma tumor growth and invasion.
        Int J Cancer. 2010; 126: 328-336
        • Wang S.
        • Wu Y.
        • Hou Y.
        • et al.
        CXCR2 macromolecular complex in pancreatic cancer: a potential therapeutic target in tumor growth.
        Transl Oncol. 2013; 6: 216-225
        • Wang B.
        • Hendricks D.T.
        • Wamunyokoli F.
        • et al.
        A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer.
        Cancer Res. 2006; 66: 3071-3077
        • Jang J.E.
        • Hold E.A.
        • Spitalnik S.L.
        • et al.
        CXCL1 and its receptor, CXCR2, mediate murine sickle cell vaso-occlusion during hemolytic transfusion reactions.
        J Clin Invest. 2011; 121: 1397-1401
        • Kuboki S.
        • Shin T.
        • Huber N.
        • et al.
        Hepatocyte signaling through CXC chemokine receptor-2 is detrimental to liver recovery after ischemia/reperfusion in mice.
        Hepatology. 2008; 48: 1213-1223
        • Son G.
        • Hirano T.
        • Seki E.
        • et al.
        Blockage of HGF/c-Met system by gene therapy (adenovirus-mediated NK4 gene) suppresses hepatocellular carcinoma in mice.
        J Hepatol. 2006; 45: 688-695
        • Hanazaki K.
        • Kajikawa S.
        • Shimozawa N.
        • et al.
        Prognostic factors of intrahepatic cholangiocarcinoma after hepatic resection: univariate and multivariate analysis.
        Hepatogastroenterology. 2002; 49: 311-316
        • Ohtsuka M.
        • Ito H.
        • Kimura F.
        • et al.
        Extended hepatic resection and outcomes in intrahepatic cholangiocarcinoma.
        J Hepatobiliary Pancreat Surg. 2003; 10: 259-264
        • Puhalla H.
        • Schuell B.
        • Pokorny H.
        • et al.
        Treatment and outcome of intrahepatic cholangiocellular carcinoma.
        Am J Surg. 2005; 189: 173-177
        • Shen W.F.
        • Zhong W.
        • Xu F.
        • et al.
        Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma.
        World J Gastroenterol. 2009; 15: 5976-5982
        • Ruffini P.A.
        • Morandi P.
        • Cabioglu N.
        • et al.
        Manipulating the chemokine-chemokine receptor network to treat cancer.
        Cancer. 2007; 109: 2392-2404
        • Han L.
        • Jiang B.
        • Wu H.
        • et al.
        High expression of CXCR2 is associated with tumorigenesis, progression, and prognosis of laryngeal squamous cell carcinoma.
        Med Oncol. 2012; 29: 2466-2472
        • Bolitho C.
        • Hahn M.A.
        • Baxter R.C.
        • et al.
        The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor.
        Endocr Relat Cancer. 2010; 17: 929-940
        • Chapman R.W.
        • Phillips J.E.
        • Hipkin R.W.
        • et al.
        CXCR2 antagonists for the treatment of pulmonary disease.
        Pharmacol Ther. 2009; 121: 55-68
        • Youngs S.J.
        • Ali S.A.
        • Taub D.D.
        • et al.
        Chemokines induce migrational responses in human breast carcinoma cell lines.
        Int J Cancer. 1997; 71: 257-266
        • Matsuo Y.
        • Campbell P.M.
        • Brekken R.A.
        • et al.
        K-Ras promotes angiogenesis mediated by immortalized human pancreatic epithelial cells through mitogen-activated protein kinase signaling pathways.
        Mol Cancer Res. 2009; 7: 799-808
        • Matsuo Y.
        • Raimondo M.
        • Woodward T.A.
        • et al.
        CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer.
        Int J Cancer. 2009; 125: 1027-1037
        • Schadendorf D.
        • Moller A.
        • Algermissen B.
        • et al.
        IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor.
        J Immunol. 1993; 151: 2667-2675
        • Bruyere C.
        • Lonez C.
        • Duray A.
        • et al.
        Considering temozolomide as a novel potential treatment for esophageal cancer.
        Cancer. 2011; 117: 2004-2016
        • Bandapalli O.R.
        • Ehrmann F.
        • Ehemann V.
        • et al.
        Down-regulation of CXCL1 inhibits tumor growth in colorectal liver metastasis.
        Cytokine. 2012; 57: 46-53
        • Wu S.
        • Singh S.
        • Varney M.L.
        • et al.
        Modulation of CXCL-8 expression in human melanoma cells regulates tumor growth, angiogenesis, invasion, and metastasis.
        Cancer Med. 2012; 1: 306-317
        • Acharyya S.
        • Oskarsson T.
        • Vanharanta S.
        • et al.
        A CXCL1 paracrine network links cancer chemoresistance and metastasis.
        Cell. 2012; 150: 165-178